Results 11 to 20 of about 4,968,206 (256)

NAA is a Marker of Disability in Secondary-Progressive MS: A Proton MR Spectroscopic Imaging Study. [PDF]

AJNR Am J Neuroradiol, 2020
BACKGROUND AND PURPOSE: The secondary progressive phase of multiple sclerosis is characterised by disability progression due to processes that lead to neurodegeneration. Surrogate markers such as those derived from MRI are beneficial in understanding the
Solanky BS, John NA, DeAngelis F, Stutters J, Prados F, Schneider T, Parker RA, Weir CJ, Monteverdi A, Plantone D, Doshi A, MacManus D, Marshall I, Barkhof F, Gandini Wheeler-Kingshott CAM, Chataway J, MS-SMART Investigators.   +16 more
europepmc   +2 more sources

Setting a research agenda for progressive multiple sclerosis: The International Collaborative on Progressive MS [PDF]

, 2012
Despite significant progress in the development of therapies for relapsing MS, progressive MS remains comparatively disappointing. Our objective, in this paper, is to review the current challenges in developing therapies for progressive MS and identify ...
Salvetti, M, D. Brown, T. Coetzee, K. Sharrock, Lee, K, Brown, D, Feinstein, A, Thompson, A, K. Zuidwijk, D. Chandraratna, Kapoor, R, Fox, RJ, Zuidwijk, K, K. Lee, A. Thompson, G. Comi, Toosy, A, Baneke, P, Browne, P, Sharrock, K, O. Ciccarelli, P. Browne, A. Feinstein, Comi, G, R. J. Fox, Chandraratna, D, P. Zaratin, Baker, D, R. Kapoor, Ciccarelli, O, Zaratin, P, P. Baneke, Coetzee, T, D. Baker, SALVETTI, Marco, A. Toosy   +35 more
core   +1 more source

Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis

Frontiers in Immunology, 2019
In the majority of patients multiple sclerosis starts with a relapsing remitting course (RRMS), which may at later times transform into secondary progressive disease (SPMS).
Hans Lassmann
doaj   +1 more source

Serum S100B in primary progressive multiple sclerosis patients treated with interferon-beta-1a. [PDF]

, 2004
S100B belongs to a family of calcium-binding proteins implicated in intracellular and extracellular regulatory activities. This study of serum S100B in primary progressive multiple sclerosis (PPMS) is based on data obtained from a randomized, controlled ...
Lim, Ee Tuan, Leary, Siobhan M, Geoff Keir, Petzold, Axel, Thompson, Alan J, Gavin Giovannoni, Siobhan M Leary, Altmann, Daniel R, Keir, Geoff, Ee Tuan Lim, David H Miller, Ed J Thompson, Giovannoni, Gavin, Miller, David H, Alan J Thompson, Daniel R Altmann, Thompson, Ed J, Axel Petzold   +17 more
core   +2 more sources

Charting a global research strategy for progressive MS-An international progressive MS Alliance proposal [PDF]

, 2021
Background: Progressive forms of multiple sclerosis (MS) affect more than 1 million individuals globally. Recent approvals of ocrelizumab for primary progressive MS and siponimod for active secondary progressive MS have opened the therapeutic door ...
Ciccarelli, Olga, Fox, Robert J, Rawlings, Sarah, Zaratin, Paola, Morahan, Julia, Marrie, Ruth Ann, Lubetzki, Catherine, Smith, Kathryn, E, Fox, Robert, J, Thompson, Alan, J, Thompson, Alan, Comi, Giancarlo, Hohlfeld, Reinhard, Donnelly, Alexis, Donnelly, Alexis A., Sincock, Caroline, Landsman, Douglas, Smith, Kathryn E, Salvetti, Marco, Kanellis, Pamela, Cross, Anne H., Feinstein, Anthony, Cross, Anne, Thompson, Alan J., Strum, Jon, Fox, Robert J., Helme, Anne, Montalban, Xavier, Musch, Bruno, Smith, Kathryn E., Sellebjerg, Finn, Hyde, Robert, Coetzee, Timothy, Universitat Autònoma de Barcelona, Carroll, William   +34 more
core   +1 more source

Altered Expression of Ion Channels in White Matter Lesions of Progressive Multiple Sclerosis: What Do We Know About Their Function?

Frontiers in Cellular Neuroscience, 2021
Despite significant advances in our understanding of the pathophysiology of multiple sclerosis (MS), knowledge about contribution of individual ion channels to axonal impairment and remyelination failure in progressive MS remains incomplete.
Francesca Boscia, Maria Louise Elkjaer, Maria Louise Elkjaer, Zsolt Illes, Zsolt Illes, Zsolt Illes, Maria Kukley, Maria Kukley   +7 more
doaj   +1 more source

Assessment of potential cardiotoxic side effects of mitoxantrone in patients with multiple sclerosis [PDF]

, 2005
Previous studies showed that mitoxantrone can reduce disability progression in patients with multiple sclerosis (MS). There is, however, concern that it may cause irreversible cardiomyopathy with reduced left ventricular (LV) ejection fraction (EF) and ...
Zingler, V. C., Hohlfeld, R., Strupp, M., Brandt, T., Jahn, K., Näbauer, M., Gross, A.   +6 more
core   +1 more source

Tau seeding in cases of multiple sclerosis

Acta Neuropathologica Communications, 2022
Relapsing remitting multiple sclerosis (MS) is an inflammatory demyelinating disorder of the central nervous system that in many cases leads to progressive MS, a neurodegenerative disease.
Michael S. LaCroix, Hilda Mirbaha, Ping Shang, Stephanie Zandee, Chan Foong, Alexandre Prat, Charles L. White, Olaf Stuve, Marc I. Diamond   +8 more
doaj   +1 more source

Genetic association of multiple sclerosis with the marker rs391745 near the endogenous retroviral locus HERV-Fc1: analysis of disease subtypes. [PDF]

PLoS ONE, 2011
We have previously described the occurrence of multiple sclerosis (MS) to be associated with human endogenous retroviruses, specifically the X-linked viral locus HERV-Fc1.
Bettina Hansen, Annette B Oturai, Hanne F Harbo, Elisabeth G Celius, Kari K Nissen, Magdalena J Laska, Helle B Søndergaard, Thor Petersen, Bjørn A Nexø   +8 more
doaj   +1 more source

Efficacy of Disease Modifying Therapies in Progressive MS and How Immune Senescence May Explain Their Failure

Frontiers in Neurology, 2022
The advent of disease modifying therapies (DMT) in the past two decades has been the cornerstone of successful clinical management of multiple sclerosis (MS).
Navid Manouchehri, Victor H. Salinas, Negar Rabi Yeganeh, David Pitt, Rehana Z. Hussain, Olaf Stuve, Olaf Stuve   +6 more
doaj   +1 more source